Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target diseases acting at the tissue level. Organ failure and systemic cancer are both the result of loss of the structural and functional integrity of normal tissue. Harnessing the body's own tissue repair process to restore tissue structure and function represents a novel and powerful new approach to treating these diseases. By combining its expertise in tissue repair mechanisms with its drug development platform, Collgard is developing breakthrough therapies for prevention and treatment of organ failure, restenosis, specific cancers, and dermal disorders.

Collgard Biopharmaceuticals Moves U.S. Headquarters From Boston To Atlanta TechLINKS, January 7, 2003 Collgard Starting Phase II Trial of Bladder Cancer Treatment Globes, December 11, 2002 Collgard Biopharmaceuticals Announces New Pre-Clinical Study Results Indicating That Tempostatin™ Reverses Existing Liver Fibrosis November 19, 2002 Has Biotechnology Strayed From its Biological Roots? Boston Business Journal, October 25, 2002 A Speedy Recovery is Not Always Best Ha'aretz, October 23, 2002 Collgard Biopharmaceuticals Announces Milestone Patent for Tempostatin™ September 24, 2002 Collgard Biopharmaceuticals Appoints New CEO Dr. Bruce Bach August 21, 2002